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INTRODUCTION: While preoperative chemotherapy (pCT) is utilized in many intra-abdominal
cancers, the use of pCT among patients with intrahepatic cholangiocarcinoma (ICC) remains ill
deﬁned. As such, the objective of the current study was to examine the impact of pCT among
patients undergoing curative-intent resection for ICC.
METHODS: Patients who underwent hepatectomy for ICC were identiﬁed from a multi-
institutional international cohort. The association between pCT with peri-operative and long-
term clinical outcomes was assessed.
RESULTS:Of the 1 057 patients who were identiﬁed and met the inclusion criteria, 62 patients
(5.9%) received pCT. These patients were noticed to have more advanced disease. Median OS
(pCT:46.9 months vs no pCT:37.4 months; P = 0.900) and DFS (pCT: 34.1 months vs no pCT:
29.1 months; P = 0.909) were similar between the two groups. In a subgroup analysis of
propensity-score matched patients, there was longer OS (pCT:46.9 months vs no pCT:29.4
months) and DFS (pCT:34.1 months vs no pCT:14.0 months); however this did not reach
statistical signiﬁcance (both P > 0.05).
CONCLUSION: In conclusion, pCTutilization among patientswith ICCwas higher among patients
with more advanced disease. Short-term post-operative outcomes were not affected by pCT
use and receipt of pCT resulted in equivalent OS and DFS following curative-intent resection.
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1 | INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) is the second most common
primary liver malignancy, accounting for 3% of all cases of gastro-
intestinal cancer.1,2 ICC makes up about 5-10% of all cholangiocarci-
nomas and originates from bile ducts within the liver parenchyma.2,3
Histologically, the majority of advanced ICC tumors are adenocarci-
noma, which are typically treated with a combination of cytotoxic
nucleoside analogs and platins.4,5 When feasible, complete surgical
resection of ICC remains the only possible option for cure with an
estimatedmedian survival ranging from 27 to 36months.6–9 However,
only a minority of patients with ICC present with surgically resectable
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disease at the time of diagnosis. Evenwith complete surgical resection,
recurrence can be as high as 50% within 24 months of surgical
resection.10 In addition, nearly one in ﬁve patients undergoing
curative-intent resection are left with microscopic disease following
surgery.11 As such, there has been interest in using preoperative
chemotherapy (pCT) to improve patient selection, increase the
incidence of margin negative surgical resection and potentially
improve disease-free (DFS) and overall survival (OS).
Preoperative chemotherapy is utilized in many intra-abdominal
cancers to reduce local disease burden and the incidence of
micrometastatic disease prior to surgical resection. In patients with
perihilar cholangiocarcinoma (PHC), recent trials have shown that pCT
may be effective in increasing DFS.12 Furthermore, in patients with
PHC, pCT can down-size locally advanced tumors in order to help
facilitate surgical resection.12 Despite this, the use of pCT among
patients with ICC has not been well-studied.5,12 As such, the objective
of the current study was to determine the impact of pCT on OS and
DFS in a large, multi-institutional international cohort of patients who
underwent curative-intent resection for ICC. Furthermore, we sought
to characterize current practice patterns regarding the use of pCT
among patients undergoing curative-intent resection for ICC.
2 | METHODS
All patients undergoing curative-intent resection for ICC between
January 1, 1990, and July 1, 2016 at one of 12 participating major
hepatobiliary institutions in the United States, Asia, Oceania, and
Europe were identiﬁed (Johns Hopkins University, Baltimore, Mary-
land; Emory University, Atlanta, Georgia; Stanford University Medical
Center, Stanford, California; University of Virginia Health System,
Charlottesville, Virginia; Fundeni Clinical Institute, Bucharest, Roma-
nia; Beaujon Hospital, Clichy, France; Curry Cabral Hospital, Lisbon,
Portugal; Eastern Hepatobiliary Surgery Hospital, Shanghai, China;
Ottowa General Hospital, Ottowa, Canada; Royal Prince Alfred
Hospital, Sydney, Australia; San Raffaele Hospital, Milan, Italy;
Erasmus University Medical Centre Rotterdam, Rotterdam, the
Netherlands). Sociodemographic and clinicopathologic data were
collected and include age, sex, and race, tumor size, AJCC stage,
histologic grade, presence of nodal metastases, ﬁnal resection margin
and the presence of vascular and/or perineural invasion.
A minor hepatectomy was deﬁned as a hepatic resection of less
than 3 Couinaud segments. Suspected lymph node metastases on
preoperative scans were considered suspicious preoperative lymph
nodes, while only pathologically proven metastases were considered
proven metastases. Patients with suspected lymph nodes preopera-
tively, and conﬁrmed lymph node metastases during pathological
examination of the resection specimen, were considered to have
lymph node disease preoperatively and postoperatively, respectively.
Patients with suspected lymph node disease preoperatively, but no
evidence in the resection specimen, were considered to only have
lymph node metastases preoperatively.
The American Joint Committee on Cancer (AJCC) 7th edition
staging was used to stratify patients by extent of disease.13 Margin
status was categorized as R0 for a negative margin, R1 when the
margin was microscopically positive and R2 when the margin was
macroscopically positive. Only patients undergoing a curative intent
surgery for histologically conﬁrmed ICC were included in the ﬁnal
study population; patients who did not undergo resection were
excluded. Patients who underwent transplantation were also
excluded. The respective institutional review boards of each
participating institution approved this study.
2.1 | Statistical analysis
Categorical variables were described as whole numbers and percen-
tages while continuous variables were reported as medians with
interquartile (IQR) range. Percentages for each variable were
calculated based on available data, excluding missing values.
Univariable comparison of categorical variables was performed using
the Pearson chi-square test. Univariable comparison of continuous
variables was performed using theMann-Whitney U-test. The primary
outcome of the study was 5-year OS. OS was calculated as the time
from the date of surgery to the date of death or date of last available
follow-up; OS was estimated using the Kaplan-Meier method. DFS
was calculated from the date of surgery to the date of ﬁrst-known
radiographically or pathologically conﬁrmed metastasis. Logistic
regression analysis was conducted in order to determine factors
associated with receipt of pCT in a multivariable model. Based on this
regression model, a propensity score was calculated to determine the
likelihood of receiving pCT. Patients were matched based on this
propensity score and OS was compared between the groups. All
analyses were performed using SPSS 22.0 (IBM, New York). All tests
were 2-sided and P < 0.05 deﬁned statistical signiﬁcance.
3 | RESULTS
3.1 | Clinical and pathologic description of patient
cohort receiving pCT
1 057 patients who underwent curative-intent resection for ICC and
met the inclusion criteria were identiﬁed; 62 patients (5.9%) received
pCT (Table 1). Among the patients who received pCT, 18 (29.0%)
patients were treated with intra-arterial chemotherapy, while the
remaining 44 patients (71.0%) were treated with systemic chemother-
apy. Median patient age among patients who received pCT was
60 years (IQR 52, 69) and the majority of the patients were male
(n = 37, 59.7%). Most patients had an ASA classiﬁcation of II or III
(n = 51, 92.7%).
Based on preoperative imaging and/or biopsy, over one-third of
patients had suspected or proven lymph node metastases (n = 21,
39.6%). We observed that patients who received systemic chemo-
therapy more frequently had suspected or conﬁrmed lymph node
metastases (n = 17, 44.7%), compared to patients who received intra-
arterial chemotherapy (n = 4, 26.7%). However, this difference did not
reach statistical signiﬁcance (P = 0.226). At the time of surgery,
approximately one-half of patients underwent a major hepatectomy
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involving more than three Couinaud segments (n = 29, 52.7%). The
majority of patients underwent a formal portal lymphadenectomy
(n = 39, 70.9%), with a median of 3 lymph nodes (IQR: 1, 6) examined.
On ﬁnal pathology, themajority of patients had anR0 resection (n = 42,
73.7%). Lymph node metastasis was noted in 24.2% of patients
(n = 15). Twelve patients (25.5%) who had lymph node metastases on
the preoperative work-up did not have lymph node metastasis on ﬁnal
pathology.
3.2 | Receipt of preoperative chemotherapy
Themajority of patientswho received pCT (n = 50)were treatedwithin
the past 10 years, however the rate of pCT remained stable over the
study period (P = 0.632). Several clinicopathologic features were
associated with receipt of pCT (Table 2). Preoperatively, patients with
suspected or biopsy-proven lymph nodes more likely received pCT
(39.6% vs 18.5%, P < 0.001). Patients who received pCT were also
more likely to have advanced disease compared with patients who did
not receive pCT. Speciﬁcally, patients with microvascular invasion
(pCT: n = 25, 48.1% vs no pCT: n = 232, 24.4%; P < 0.001) and
perineural invasion (pCT: n = 15, 30.6% vs no pCT: n = 137, 15.6%;
P = 0.006) more commonly received pCT. Furthermore, based on the
AJCC 7th edition staging system, patients who received pCT more
commonly had stage III or IV disease (pCT: n = 16, 55.2% vs no pCT:
n = 146, 24.7; P < 0.001). The presence of extrahepatic disease
was also associated with receipt of pCT (pCT: n = 8, 12.9% vs no
pCT: n = 32, 3.2; P < 0.001). On ﬁnal pathology, patients who received
pCT also more often had microscopic R1 (pCT: n = 14, 24.6% vs
no pCT: n = 120, 12.4%; or macroscopic R2 (pCT: n = 1, 1.8% vs no
pCT: n = 4, 0.4%; P = 0.010) resections.
On multivariable analysis, after controlling for all measurable
confounders, factors associated with receipt of pCT included major
hepatic resection (OR: 3.88, 95%CI 1.43-10.49, P = 0.008) and the
presence of microvascular invasion (OR: 2.93, 95%CI 1.43-6.02,
P = 0.003).
3.3 | Perioperative morbidity
Overall morbidity among all patients who underwent resection for ICC
was 40.2% (n = 420)with a higher incidence of complications occurring
among patients who received pCT (pCT: n = 36, 59.0% vs no pCT:
n = 384, 39.0%; P = 0.002); major morbidity, however, did not differ
between the two groups (P = 0.568) (Table 3). Median length of stay
(pCT: 9 days, IQR 6,15 vs no pCT: 12 days, IQR 7,17; P = 0.080) and
perioperative mortality within 90 days of surgery (pCT: n = 1, 2.2% vs
no pCT: n = 35, 3.9%; P = 0.569) also did not differ between the two
groups. Readmission within 30 days from surgery, however, was more
common among patients who received pCT (pCT: n = 8, 15.7% vs no
pCT: n = 39, 4.8%; P = 0.001). Post-operatively, patients in the pCT
group more often received adjuvant chemotherapy (50.8% vs 29.0%,
P = 0.001).
3.4 | Impact of preoperative chemotherapy on
overall and disease-free survival
At a median follow-up of 27.6 months, mortality occurred in 522
(49.7%) patients. Median OS among the entire cohort was 37.4
months (95%CI 32.5-42.3 months) with 1-, 3-, and 5-year OS being
78.9%, 51.4%, and 39.2%, respectively. Stratiﬁed by receipt of pCT,
median OS was similar between the two groups (pCT: 46.9 months,
TABLE 1 Characteristics of the preoperative chemotherapy group
(n = 62)





















Intra-arterial therapy 18 (29.0)
Systemic therapy 44 (71.0)





Minor hepatectomy (<3 segments) 6 (10.9)
Right hepatectomy 9 (16.4)
Left hepatectomy 8 (14.5)
Extended right hepatectomy 18 (32.7)
Extended left hepatectomy 11 (20.0)
Central hepatectomy 3 (5.5)
Lymphadenectomy 39 (70.9)
Lymph nodes harvested 3 (1-6)
Lymph node metastases 15 (24.2)
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95%CI 28.5-65.2 months vs no pCT: 37.4 months, 95%CI 32.3-42.5
months; P = 0.900; Fig. 1). Disease recurrence occurred in 454 (43.0%)
patients. Median DFS among the entire cohort was 29.6 months (95%
CI 17.2-42.0 months) with 1-, 3-, and 5-year DFS being 64.7%, 46.6%,
and 44.4%, respectively. Stratiﬁed by receipt of pCT, median DFS was
also similar between the two groups (pCT: 34.1 months, 95%CI
2.5-65.7 months vs no pCT: 29.1 months, 95%CI 16.0-42.2 months;
P = 0.909; Fig. 2).
In a subgroup analysis of propensity-score matched patients
based on the factors associated with receipt of pCT (n = 100), there
was longer OS in the pCT group (pCT: 46.9 months, 95%CI 24.3-69.4
months vs no pCT: 29.4 months, 95%CI 14.5-44.4 months), however
this did not reach statistical signiﬁcance (P = 0.136; Fig. 3). Similarly,
there was suggestion of an improved DFS in the pCT group (pCT: 34.1
months, 95%CI 0-70.2 months vs no pCT:14.0 months, 95%CI
7.0-20.9 months; P = 0.551).
4 | DISCUSSION
Preoperative therapy is used in several intra-abdominal cancers to
reduce local and micrometastatic tumor burden prior to complete
surgical resection. Some beneﬁts of pCT include the potential to
down-size tumors to increase resectability rates among patients who
are initially deemed unresectable. Furthermore, pCT can potentially
improve completeness of surgical resection, as well as help select
patients with a better tumor biology, thereby improving OS and DFS.
In the current study, we examined a large, multi-institutional
TABLE 2 Comparison of disease characteristics across treatment groups
Variable No Preoperative Chemotherapy (n = 995) Preoperative Chemotherapy (n = 62) P-value
Preoperative lymph node metastases <0.001
No 699 (81.2) 32 (60.4)
Suspicious 121 (14.1) 12 (22.6)
Proven 38 (4.4) 9 (17.0)
Type of resection <0.001
Minor hepatectomy (<3 segments) 413 (42.6) 6 (10.9)
Right hepatectomy 158 (16.3) 9 (16.4)
Left hepatectomy 185 (19.1) 8 (14.5)
Extended right hepatectomy 110 (11.4) 18 (32.7)
Extended left hepatectomy 85 (8.8) 11 (20.0)
Central hepatectomy 18 (1.9) 3 (5.5)
Number of tumors 1 (1-1) 1 (1-1) 0.207
Tumor size (cm) 6.0 (4.2-8.8) 7.1 (5.0-10.2) 0.069
Major vascular invasion 95 (9.8) 5 (8.9) 0.832
Microvascular invasion 232 (24.4) 25 (48.1) < 0.001
Perineural invasion 137 (15.6) 15 (30.6) 0.006
Invasion of adjacent organs 72 (7.4) 5 (8.9) 0.676
Satellite lesions 216 (22.2) 17 (29.8) 0.181
Intrahepatic metastases 69 (7.1) 6 (10.7) 0.308
Lymphadenectomy 424 (43.7) 39 (70.9) < 0.001
Lymph nodes harvested 2 (0-5) 3 (1-6) 0.074
Lymph node metastases 169 (17.0) 15 (24.2) 0.146
Extrahepatic metastases 32 (3.2) 8 (12.9) < 0.001
Margin status 0.010
R0 840 (87.1) 42 (73.7)
R1 120 (12.4) 14 (24.6)
R2 4 (0.4) 1 (1.8)
AJCC stage < 0.001
I 282 (48.0) 7 (24.1)
II 160 (27.2) 6 (20.7)
III 22 (3.7) 6 (20.7)
IVA 112 (19.0) 8 (27.6)
IVB 12 (2.0) 2 (6.9)
BUETTNER ET AL. | 315
international cohort of patients receiving pCT for ICC. As the use of
pCT among patients with ICC has not been well-studied, this
represents to our knowledge the largest study to date analyzing the
impact of pCT among patients undergoing curative-intent resection
for ICC. We noted that patients with more advanced disease were
more likely to receive pCT. Of note, the use of pCT did result in higher
overall but not major perioperative morbidity. Furthermore, in the
propensity score-matched cohort, there was a suggestion that pCT
improved OS and DFS, however these differences did not reach
statistical signiﬁcance perhaps due to a small sample size.
The use of pCT has not been examined among patients with ICC in
any prospective clinical trial to date. Likely due to the overall low
incidence of ICC, patients with ICC are often grouped in clinical trials
with other patientswithbiliary tract cancers. As such, the beneﬁt of pCT
in patients with ICC is ill-deﬁned and not commonly utilized.2,14–16 In
fact, in the current multi-institutional international cohort, the overall
utilization of pCT was only 5.9%. This is likely due to the fact that
analyses fromavailable studieshavebeenunable toshowa reproducible
beneﬁt with the use of pCT among patients with ICC.2,16 Among
patients with pancreatic adenocarcinoma, however, pCT has been used
in patients with locally advanced tumors to deﬁne the tumor biology.17
In the current cohort, patients with more advanced disease were more
likely to receive pCT − suggesting that physicians were using pCT, in
part, to help deﬁne the natural history of the disease. Speciﬁcally,
patients with more preoperative suspected or biopsy-proven lymph
node metastasis, as well as those patients with worse pathological
tumor features more commonly received pCT. Unfortunately, as the
current cohort only included patients undergoing curative-intent
hepatic resection for ICC, we were unable to determine the rate of
resectability among patients with locally advanced disease. Of note, on
ﬁnal pathology, the use of pCT did not improve complete R0 resection
rates. This is likely multifactorial, but largely be due to the selection of
pCT use for patients with tumors characterized by worse pathological
features.
Patients who received pCT had increased minor, but not major
perioperative morbidity or mortality rates versus patients who did not
receive pCT. This is similar to previously published data regarding the
safety of pCT among patients undergoing resection for intra-
abdominal cancer.18,19 Despite having more advanced disease and
undergoing larger hepatic resections, patients who received pCT had
equivalent peri-operative mortality and LOS. While long-term OS and
DFS were comparable among patients who did and did not receive
pCT, propensity score-matched analysis suggested a possible beneﬁt
of pCT regarding both OS and DFS—although the association did not
TABLE 3 Comparison of postoperative course and follow-up across treatment groups
Variable No preoperative chemotherapy (n = 995) Preoperative chemotherapy (n = 62) P-value
Complication 384 (39.0) 36 (59.0) 0.002
Clavien dindo grade 0.568
I-II 239 (58.0) 23 (53.5)
III-V 173 (42.0) 20 (46.5)
Length of stay (days) 12 (7-17) 9 (6-15) 0.080
Readmission within 30 days 39 (4.8) 8 (15.7) 0.001
Postoperative mortality 35 (3.9) 1 (2.2) 0.569
Adjuvant therapy
Adjuvant intra-arterial therapy 102 (14.1) 7 (14.6) 0.921
Adjuvant chemotherapy 270 (29.0) 30 (50.8) 0.001
Adjuvant radiotherapy 56 (6.4) 6 (10.7) 0.203
FIGURE 1 Overall survival stratiﬁed by preoperative chemother-
apy (P = 0.900)
FIGURE 2 Disease free survival stratiﬁed by preoperative chemo-
therapy (P = 0.909)
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reach statistical signiﬁcance. While it is difﬁcult to know, the lack of
signiﬁcance, despite the considerable differences in the point
estimates, was likely due to a type II statistical error given the very
low utilization of pCT in the current cohort. Nelson et al had reported
that the use of pCT combinedwith radiation therapy improved survival
outcomes among patients with extrahepatic cholangiogcarcinoma.20
In a different study, Tamandl et al reported on 10 patients with ICC
who were treated with pCT and noted no survival beneﬁt.21While the
current study was one of the largest series to examine ICC patients to
receive pCT (n = 62), we similarly failed to ﬁnd an effect of pCT on
long-term outcomes. As noted, however, the sample size was still
relatively small and therefore future prospective studies are needed.
In this study, we included 18 patients who received preoperative
intra-arterial chemotherapy, as opposed to the 44 patients who
received systemic chemotherapy. Intra-arterial therapy consists of the
delivery of high doses of chemotherapy directly to the arterial
circulation.9 This results in high ﬁrst pass extraction rates and
minimizes systemic toxicity, as tumors derive most of their supply
from the arterial circulation.9,22 The effects of intra-arterial therapy
have been described in two clinical trials and a retrospective analysis,
which showed promising results in patients with liver-conﬁned disease
in a palliative setting.9,23,24 In our cohort, the lower percentage of
patients with preoperatively conﬁrmed lymph node metastases in the
intra-arterial chemotherapy group (26.7% vs 44.7%), suggests that
intra-arterial therapy was most often used preoperatively in patients
with suspected borderline resectable disease, as opposed to patients
with suspected micrometastatic disease. Although our ﬁnding is in line
with current literature on patients with irresectable disease, future
studies are needed to conﬁrm the validity of this approach prior to a
curative resection.
Results of the current study should be interpreted in the context
of several limitations. As noted, the number of patients treated with
pCT was small as the overall utilization was only 5.9%. Therefore, the
lack of statistical signiﬁcance was likely related to a type II error.
Additionally, inherent to all retrospective analyses, there may have
been a selection bias regarding the diagnosis and treatment of
patients. The inclusion of multiple centers also did not allow for the
standardization of operative approach or protocols related to the use
of pCT or adjuvant chemotherapy. The multi-center nature of the
study adds to the generalizability of the study, allowing the ﬁnding to
be applied across a wide range of patient populations.
5 | CONCLUSIONS
In conclusion, pCT utilization among patients with ICC is higher among
patients with more advanced disease. In this large, multi-institutional
cohort, the use of pCT did not impact short-term peri-operative
outcomes such as morbidity or LOS. While OS and DFS following
resection were not signiﬁcantly different across treatment groups,
propensity matching suggested possible improved outcomes in
patients treated with pCT. Further prospective trials are needed,
however, to better deﬁne the role of pCT and to identify the subset of
patients who might yield the most clinical beneﬁt from the use of pCT.
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